BRPI0821660A2 - Combinações de agentes terapêuticos para tratamento de câncer - Google Patents

Combinações de agentes terapêuticos para tratamento de câncer

Info

Publication number
BRPI0821660A2
BRPI0821660A2 BRPI0821660-6A BRPI0821660A BRPI0821660A2 BR PI0821660 A2 BRPI0821660 A2 BR PI0821660A2 BR PI0821660 A BRPI0821660 A BR PI0821660A BR PI0821660 A2 BRPI0821660 A2 BR PI0821660A2
Authority
BR
Brazil
Prior art keywords
combinations
therapeutic agents
cancer treatment
cancer
treatment
Prior art date
Application number
BRPI0821660-6A
Other languages
English (en)
Inventor
Dean Brent Evans
Christian J Jacques
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0821660A2 publication Critical patent/BRPI0821660A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0821660-6A 2007-12-13 2008-12-04 Combinações de agentes terapêuticos para tratamento de câncer BRPI0821660A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1333507P 2007-12-13 2007-12-13
PCT/US2008/085535 WO2009076170A2 (en) 2007-12-13 2008-12-04 Combinations of therapeutic agents for treating cancer

Publications (1)

Publication Number Publication Date
BRPI0821660A2 true BRPI0821660A2 (pt) 2015-06-16

Family

ID=40404865

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821660-6A BRPI0821660A2 (pt) 2007-12-13 2008-12-04 Combinações de agentes terapêuticos para tratamento de câncer

Country Status (10)

Country Link
US (1) US20100272717A1 (pt)
EP (1) EP2231147A2 (pt)
JP (1) JP2011506455A (pt)
KR (1) KR20100103819A (pt)
CN (1) CN101896177A (pt)
AU (1) AU2008335469A1 (pt)
BR (1) BRPI0821660A2 (pt)
CA (1) CA2708149A1 (pt)
RU (1) RU2010128239A (pt)
WO (1) WO2009076170A2 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8178564B2 (en) 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
CA2736361C (en) * 2008-10-31 2017-10-10 Novartis Ag Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
CA2760179A1 (en) * 2009-05-15 2010-11-18 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and an antidiabetic compound
EP2464347A1 (en) * 2009-08-11 2012-06-20 Novartis AG Combinations of vascular disrupting agents with inhibitor of apoptosis proteins antagonists
US8383607B2 (en) 2010-03-31 2013-02-26 Aeterna Zentaris Gmbh Perifosine and capecitabine as a combined treatment for cancer
WO2012064967A2 (en) * 2010-11-10 2012-05-18 Cedars-Sinai Medical Center Cancer cell-derived receptor activator of the nf-kb ligand drives bone and soft tissue metastases
KR20130124961A (ko) * 2010-12-09 2013-11-15 에프. 호프만-라 로슈 아게 베바시주맙 병용 치료를 위한 마커로서의 agtr1
FR2968557A1 (fr) * 2010-12-09 2012-06-15 Sanofi Aventis Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab
CN102212511A (zh) * 2011-03-31 2011-10-12 山东大学 定点突变的嗜热菌f3因子重组蛋白及其应用
EP2714038A1 (en) * 2011-05-24 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/pi3k inhibitors
CN103889987B (zh) 2011-07-19 2016-09-14 默沙东有限责任公司 作为btk抑制剂的选择的咪唑并吡嗪类
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
US9399035B2 (en) * 2012-03-06 2016-07-26 The Board Of Trustees Of The University Of Illinois Procaspase 3 activation by combination therapy
WO2013142817A2 (en) 2012-03-23 2013-09-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
CN104349779A (zh) * 2012-05-16 2015-02-11 诺华股份有限公司 Pi-3激酶抑制剂的剂量方案
US9561245B2 (en) 2012-09-06 2017-02-07 The Board Of Regents Of The University Of Texas System Combination treatments for melanoma
RU2541810C2 (ru) * 2013-05-23 2015-02-20 Закрытое Акционерное Общество "Фарм-Синтез" Способ лечения рака предстательной железы с использованием пролонгированной депо формы октреотида на фоне хирургической или медикаментозной кастрации
US9572828B2 (en) 2013-07-18 2017-02-21 The Board Of Regents Of The University Of Texas System Treatment for melanoma
EP4772247A2 (en) 2013-08-14 2026-07-08 Novartis AG Combination therapy comprising ribociclib and fulvestrant for the treatment of cancer
EP3076974A1 (en) 2013-12-05 2016-10-12 Acerta Pharma B.V. Therapeutic combination of a pi3k inhibitor and a btk inhibitor
US10272083B2 (en) 2014-01-21 2019-04-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
WO2015148839A1 (en) * 2014-03-26 2015-10-01 City Of Hope Treatment of brca1-defective cancer or resistant cancers
US9937171B2 (en) 2014-04-11 2018-04-10 Acerta Pharma B.V. Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
EP3148532B1 (en) 2014-05-28 2021-03-03 Piramal Enterprises Limited Pharmaceutical combination comprising a cdk inhibitor and a thioredoxin reductase inhibitor for the treatment of cancer
MX388409B (es) * 2014-06-12 2025-03-19 Cedars Sinai Medical Center Composiciones y metodos para tratar canceres.
WO2015193740A2 (en) 2014-06-17 2015-12-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor
WO2016003886A1 (en) * 2014-07-02 2016-01-07 Lam Therapeutics, Inc. 4-aminoquinoline compositions and methods for using same
SMT202100674T1 (it) 2014-08-11 2022-01-10 Acerta Pharma Bv Combinazioni terapeutiche di un inibitore di btk e un inibitore di bcl-2
EP3006453A1 (en) 2014-10-08 2016-04-13 Cosmo Technologies Ltd. 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors
CN104983735B (zh) * 2015-06-30 2018-09-14 上海交通大学 Estrone在制备抗卵巢癌和/或乳腺癌产品中的应用
WO2017000080A1 (zh) * 2015-06-30 2017-01-05 上海交通大学 Estrone在制备抗卵巢癌和/或乳腺癌产品中的应用
IL293821A (en) 2015-07-02 2022-08-01 Acerta Pharma Bv Solid forms and formulations of (S)-4-(8-amino-3-(1-(but-2-aminoyl)pyrrolidine-2-yl)imidazo[5,1-yl]pyrazin-1-yl)-en- (pyridine-2-yl)benzamide
AU2017206718B2 (en) * 2016-01-11 2021-09-30 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
FR3046949A1 (fr) * 2016-01-22 2017-07-28 Anne-Laure Morel Nanoparticules d'or et procede ecologique de preparation
CN105963305B (zh) * 2016-07-05 2018-08-17 福州大学 一种含酪氨酸激酶抑制剂的药物组合物及其在制备抗肿瘤转移药物中的应用
CN105998033B (zh) * 2016-07-05 2018-11-27 福州大学 一种含有厄洛替尼和熊果酸的药物组合物及其在制备抗肿瘤药物中的应用
RU2752172C2 (ru) * 2016-08-31 2021-07-23 Фуджифилм Корпорэйшн Противоопухолевый агент, усилитель противоопухолевого действия и противоопухолевый набор
US9980953B2 (en) * 2016-09-26 2018-05-29 Chong Kun Dang Pharmaceutical Corp. Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a VDA and topoisomerase inhibitor
KR101878650B1 (ko) * 2016-10-26 2018-07-16 연세대학교 산학협력단 내성암의 내성 극복 또는 치료용 약학 조성물
EP3606536A4 (en) * 2017-04-04 2020-12-16 University of Miami INDICATIVE BIOMARKERS OF PROSTATE CANCER AND RELATED TREATMENT
CN109985244A (zh) * 2017-12-29 2019-07-09 广州威溶特医药科技有限公司 E3连接酶抑制剂和溶瘤病毒在制备抗肿瘤药物的应用
MX2018002611A (es) 2018-01-29 2019-07-30 Fujifilm Corp Agente antitumoral para cancer del tracto biliar y metodo para tratar cancer del tracto biliar.
CN110833544B (zh) * 2018-08-17 2022-08-09 深圳微芯生物科技股份有限公司 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途
CN109260197B (zh) * 2018-10-08 2021-02-12 中国医学科学院血液病医院(中国医学科学院血液学研究所) 靛玉红类化合物和硼替佐米在制备治疗多发性骨髓瘤的药物中的用途
US11612577B2 (en) 2018-10-26 2023-03-28 Syndevrx, Inc. Biomarkers of METAP2 inhibitors and applications thereof
CA3142157A1 (en) * 2019-05-30 2020-12-03 The Board Of Trustees Of The University Of Illinois Procaspase-3 activation and immunotherapy for treatment of cancer
CN116763794B (zh) * 2022-03-11 2025-06-03 四川大学华西医院 1,7-二氢-6h-嘌呤-6-酮化合物在制备抗肺纤维化药物中的应用
CN117883451B (zh) * 2024-01-12 2026-06-26 湖南中医药大学 一种治疗肿瘤的药物、脂质体、制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1287854T3 (da) * 2001-08-30 2006-04-03 Cancer Rec Tech Ltd Kombinationer, der modvirker kræft
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB0321999D0 (en) * 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
BRPI0614965A2 (pt) * 2005-08-26 2016-09-13 Antisoma Plc método para a modulação de crescimento neoplástico, usos de um composto ou, um sal, éster ou pró-droga farmaceuticamente aceitável do mesmo, de um aglutinante do fator de crescimento endotelial vascular, e de um taxano, formulação farmacêutica, e, kit

Also Published As

Publication number Publication date
WO2009076170A2 (en) 2009-06-18
WO2009076170A3 (en) 2009-07-30
US20100272717A1 (en) 2010-10-28
EP2231147A2 (en) 2010-09-29
CA2708149A1 (en) 2009-06-18
AU2008335469A1 (en) 2009-06-18
RU2010128239A (ru) 2012-01-20
JP2011506455A (ja) 2011-03-03
KR20100103819A (ko) 2010-09-28
CN101896177A (zh) 2010-11-24

Similar Documents

Publication Publication Date Title
BRPI0821779A2 (pt) tratamento terapêutico de câncer
BRPI0810082A2 (pt) 3-imidazolil-indóis para o tratamento de doenças proliferativas
HUE054495T2 (hu) Rák kezelésére szolgáló készítmény
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
DK2121139T3 (da) Formulations for cancer treatment
BRPI0716435A2 (pt) Compostos para o tratamento de doenças proliferativas
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
ZA200905159B (en) Combination of LBH589 with other therapeutic agents for treating cancer
CY2014006I1 (el) Μεθοδοι θεραπευτικης αγωγης χρησιμοποιωντας γλυκοπεγκυλιωμενο g-csf
BRPI0922771A2 (pt) agentes indutores de apoptose seletivos para bcl-2 para o tratamento de câncer e doenças imunes
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
BRPI0807987A2 (pt) Terapia de combinação para tratamento de distúrbios imunes.
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
BRPI1008566A2 (pt) métodos e composições para o diagnóstico e tratamento de câncer
PL2338519T3 (pl) Środek do leczenia zwłóknienia szpiku
DK2154971T3 (da) Synergistisk farmaceutisk kombination til behandling af cancer
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
BRPI0922884A2 (pt) compostos para tratamento de câncer
BRPI0813670A2 (pt) Compostos para tratamento
BRPI0821248A2 (pt) Inibidores de cinesina como fármacos terapêuticos para câncer
BRPI0815551A2 (pt) Tratamento através de hucbc de doença beta-amiloide
BRPI1010874A2 (pt) composição para o tratamento de câncer de próstata
BRPI0821145A2 (pt) Agente terapêutico para prurido
BRPI1009448A2 (pt) combinações farmacêuticas compreendendo edea119/bay 869766 para o tratamento de cânceres específicos
HUE038563T2 (hu) Rák kezelési eljárás

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.